Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Keywords
COVID-19
Cytokine release syndrome
Tocilizumab
IL-6
IL-6R
Cited by (0)
- 1
Present address: Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
© 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.